Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Nigel Legg"'
Publikováno v:
European Neurology. 42:173-179
Rizatriptan (MAXALTTM, Merck & Co., Inc.) is a selective 5-HT1B/1D receptor agonist with rapid oral absorption and early onset of action for the acute treatment of migraine. This randomized, double-masked, double-dummy, placebo-controlled study compa
Autor:
Dimitri Tousoulis, Adam Crisp, Nigel Legg, Duncan J Anderson, Paul D O B Winter, Roberto Lorenzoni, Tomaso Gnecchi-Ruscone, Paolo G. Camici
Publikováno v:
The American Journal of Cardiology. 81:1165-1168
The effects of intravenous ergotamine (0.25 mg) on basal and hyperemic (dipyridamole) myocardial blood flow (MBF), measured with positron emission tomography and H2(15)O, were assessed in 15 migraineurs in a double-blind, randomized, placebo controll
Publikováno v:
Journal of neurology, neurosurgery, and psychiatry. 69(4)
OBJECTIVES To investigate visual function in migraine using visual evoked potentials. METHODS Electroretinograms (ERGs) and visual evoked potentials (VEPs) to single flash (SF) and pattern reversal (PR) stimuli were studied in 92 migraine subjects an
Autor:
Nigel Legg, Jacques Melin, X. Bernard, Adam Crisp, Duncan J Anderson, Paolo G. Camici, P. Pierre, P. D O Winter, Tomaso Gnecchi-Ruscone, H. Enahoro
Publikováno v:
Neurology. 55(1)
Background: Migraine drugs can produce adverse cardiac effects. The authors have demonstrated previously that ergotamine can lead to a significant reduction of hyperemic myocardial blood flow, but little is known about the effect of the newer seroton
Autor:
Nigel Legg, Nofal M Khalil
Publikováno v:
Cephalalgia : an international journal of headache. 15(6)
Autor:
Roberto Lorenzoni, Flemming Hermansen, Dimitris Tousoulis, Tomaso Gnecchi-Ruscone, Gillian Shepherd, Nigel Legg, Paolo G. Camici
Publikováno v:
Journal of Nuclear Cardiology. 4:S64
Autor:
Nigel Legg, JamesM.B. Burn
Publikováno v:
The Lancet. 288:1074-1075
Autor:
Nigel Legg
Publikováno v:
BMJ. 1:1235-1235